Imugene Doses First Patient in BTKi Combination Cohort of azer-cel Phase 1b Study
Key points
- First patient dosed in BTKi combination cohort of azer-cel Phase 1b study
- Patient with Mantle Cell Lymphoma (MCL) who failed prior BTKi therapy
- Aim to explore improved activity of azer-cel and BTKi in combination
Full summary
Imugene Limited (ASX: IMU) has announced the enrollment of the first patient in the BTK inhibitor (BTKi) combination cohort of its ongoing Phase 1b basket study of azer-cel, an off-the-shelf CAR T cell therapy. The patient, diagnosed with Mantle Cell Lymphoma (MCL) and having failed prior BTKi therapy, is part of a cohort evaluating the safety and preliminary efficacy of azer-cel in combination with a BTKi. This expansion of the clinical scope aims to explore whether concurrent treatment may enhance the activity of azer-cel and BTKi, addressing a significant unmet medical need as many patients develop resistance or intolerance to BTKi therapy.
Summary generated by a large language model. Please interpret with care.